[Decision on the immunomodulating therapy in unspecific osteomyelitis of the spine].
Vishnevskiĭ. A A AA; Orlov. A B AB; Tikhodeev. S A SA
Key Findings
- T‑cell immunity is often impaired in unspecific osteomyelitis of the spine
- Cytomedins such as thymalin are recommended when T‑cell function is low
- Different immune deficits (T‑cell vs. B‑cell) call for different supplemental drugs
Practical Outcomes
- For most biohackers focused on health optimization, this research offers limited direct use because it concerns serious spinal infections, not healthy individuals. It does suggest that thymalin may help boost T‑cell function in disease settings, but any use should be under medical supervision and is not a general longevity or performance protocol.
Summary
The study looked at 54 people with spine infections and found that many had weak T‑cell immunity. The authors suggest adding immune‑boosting drugs like thymalin (a peptide that supports T‑cells) to the standard infection treatment, while other drugs are recommended if B‑cells are weak.
Abstract
Immunomodulating therapy was used in treatment of 54 patients with unspecific osteomyelitis of the spine (UOS). The age of the patients was from 15 through 76 years. The authors consider that immunocorrection should be included in the complex of obligatory measures of treatment of patients with purulent infections of the spine and is dependent on the type of immunological impairments. For its success it is necessary to determine the type and degree of immunity impairment. Since in most cases of UOS there is a disorder in the T-cell link of immunity, it is preferable to use cytomedins (T-activin, thymalin, thymogen etc) or cytokines (e.g. roncoleukin). In cases of an insufficient B-cell link the medicines of choice are licopid and myelopid.
Study Information
pubmed
2006